Intra-Cellular Therapies Full Year 2023 Earnings: EPS Beats Expectations
Intra-Cellular Therapies (NASDAQ:ITCI) Full Year 2023 Results
Key Financial Results
Revenue: US$464.4m (up 86% from FY 2022).
Net loss: US$139.7m (loss narrowed by 46% from FY 2022).
US$1.46 loss per share (improved from US$2.73 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Intra-Cellular Therapies EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 10%.
Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 7.3% from a week ago.
Risk Analysis
It is worth noting though that we have found 1 warning sign for Intra-Cellular Therapies that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
